NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Older Adult Oncology. These NCCN Guidelines® are currently available as Version 2.2016.
- September 16, 2016
- Clinical Practice Updates
NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Older Adult Oncology. These NCCN Guidelines® are currently available as Version 2.2016.
- Disease-Specific Issues Related to Age/Central Nervous System Cancers: (OAO-B 8 of 32)
- The recommendations for adjuvant therapy for newly diagnosed patients with glioblastoma multiforme (GBM) were revised as follows based on the recent report from a global randomized phase III clinical trial.
- Hypofractionated accelerated course RT with concurrent and adjuvant temozolomide is safe in older patients, and may have comparable survival and less toxicity to standard fractionated RT with concurrent and adjuvant temozolomide. Hypofractionated accelerated course RT with concurrent and adjuvant temozolomide has been shown to be superior to hypofractionated accelerated course of RT alone in a randomized controlled trial of newly diagnosed GBM patients 65 years of age.
- The recommendations for adjuvant therapy for newly diagnosed patients with glioblastoma multiforme (GBM) were revised as follows based on the recent report from a global randomized phase III clinical trial.
NCCN has published updates to the NCCN Drugs & Biologics Compendium (NCCN Compendium®) to reflect updates to the 2016 Version of the corresponding NCCN Guidelines:
Ovarian Cancer, Version 1.2016 more >
